Final answer:
C1 esterase inhibitor deficiency is treated with concentrated C1-INH from blood donors, and various therapeutic drugs are in development or approved for managing hereditary angioedema. Research on Michael acceptor cysteine protease inhibitors indicates potential for treating infectious diseases.
Step-by-step explanation:
Treatment for C1 esterase inhibitor (C1-INH) deficiency, which is associated with conditions such as hereditary angioedema, includes the administration of purified and concentrated C1-INH from blood donors. This treatment can prevent severe outcomes and improve the quality of life for those affected. Although there is no cure for hereditary angioedema, various therapeutic drugs are either approved or undergoing late-stage clinical trials to manage symptoms and prevent attacks.
Additionally, research has shown that certain electrophilic compounds, including Michael acceptor cysteine protease inhibitors, which have a peptide component that binds to the target enzyme, could be employed in the treatment of infectious diseases. These inhibitors have demonstrated potential utility in therapeutics against diseases like malaria, Chagas' disease, and the common cold.